Novel anticoagulant, direct factor Xa inhibitor: Rivaroxaban

Abstract

Abstract: Anticoagulants are recommended for the prevention and treatment of a wide variety of thromboembolic events.Although existing anticoagulants are effective , their usage is limited by parenteral administration or the requirement for frequent monitoring and subsequent dose adjustment.Therefore , there is an urgent need for novel , oral agents with a predictable anticoagulant action.Because of its key position in the coagulation cascade and its limited roles outside of coagulation, Factor Xa has presented as an attractive target for novel anticoagulants.As a result , the past decade has witnessed an explosion of research into small-molecule, oral , direct Factor Xa inhibitors , and some are now in clinical development.Rivaroxaban is currently furthest ahead in its developmental program, having entered phase III in 3 indications.It is hoped that , before long , these anticoagulants will allow us to enter an era of convenient , oral anticoagulation , without the need for regular monitoring or dose adjustment.

Key words: anticoagulant, Factor Xa inhibitor, Rivaroxaban, vein thrombosis, acute coronary syndrome, atrial fibrillation

CLC Number:

R973+.2

KE Yong-sheng. Novel anticoagulant, direct factor Xa inhibitor: Rivaroxaban[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(4): 361-367.

References

[1] Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy [J].Chest,2004, 126(3 Suppl):338S-400S.
[2] Ansell J, Hirsh J, Poller L, et al.The pharmacology and management of the vitamin K antagonists:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy[J].Chest, 2004, 126(3 Suppl):204S-233S.
[3] Shimizu T, Nishihira J, Watanabe H, et al.Macrophage migration inhibitory factor is induced by thrombin and factor Xa in endothelial cells[J].J Biol Chem, 2004, 279(14):13729-13737.
[4] Vesey DA, Cheung CW, Kruger WA, et al.Thrombin stimulates proinflammatory and proliferative responses in primary cultures of human proximal tubule cells[J].Kidney Int, 2005, 67(4):1315-1329.
[5] Tarzami ST, Wang G, Li W, et al.Thrombin and PAR-1 stimulate differentiation of bone marrow-derived endothelial progenitor cells[J].J Thromb Haemost, 2006, 4(3):656-663.
[6] Bauer KA.New anticoagulants:anti IIa vs anti Xa-is one better[J]? J Thromb Thrombolysis, 2006, 21(1):67-72.
[7] Hermans C, Claeys D.Review of the rebound phenomenon in new anticoagulant treatments[J].Curr Med Res Opin, 2006, 22(3):471-481.
[8] Turpie AG, Bauer KA, Eriksson BI, et al.Fondaparinuxvs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery:a meta-analysis of 4 randomized double-blind studies [J].Arch Intern Med,2002, 162(16):1833-1840.
[9] Samama MM, Gerotziafas GT, Elalamy I, et al.Biochemistry and clinical pharmcology of new anticoagulant agents[J].Pathophysiol Haemost Thromb, 2002, 32(56):218-224.
[10] Perzborn E, Strassburger J, Wilmen A, et al.In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor[J].J Thromb Haemost, 2005, 3(3):514-521.
[11] Walenga JM, Hoppensteadt D, Iqbal O, et al.The oral,direct factor Xa inhibitor BAY 59-7939 does not cross-react with anti-heparin PF4 (heparin-induced thrombocytopenia)antibodies[J].Blood, 2005, 106:Abstract 1883.
[12] Kubitza D, Becka M, Voith B, et al.Safety, pharmacodynamics,and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor[J].Clin Pharmacol Ther, 2005, 78(4):412-421.
[13] Kubitza D, BeckaM, Wensing G, et al.Safety, pharmacodynamics,and pharmacokinetics of BAY 59-7939-anoral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects[J].Eur J Clin Pharmacol, 2005, 61(12):873-880.
[14] Kubitza D, BeckaM, MueckW, et al.Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban-an oral, direct Factor Xa inhibitor-are not affected by aspirin[J].J Clin Pharmacol, 2006, 46(9):981-990.
[15] Kubitza D, Becka M, Zuehlsdorf M, et al.No interaction between the novel, oral direct Factor Xa inhibitor BAY 59-7939 and digoxin[J].J Clin Pharmacol, 2006, 46:702.
[16] Kubitza D, Mueck W, Becka M.The oral, direct Factor Xa inhibitor BAY 59-7939 does not prolong the QTc interval[J].J Clin Pharmacol, 2006, 46:703.
[17] Eriksson BI, Borris LC, Dahl OE, et al.Rivaroxaban for prevention of venous thromboembolism after hip replacement:a phase IIa proof-of-principle study[J].Pathophysiol Haemost Thromb, 2006, 35:A33.
[18] Eriksson BI, Borris L, Dahl OE, et al.Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement[J].J Thromb Haemost, 2006, 4(1):121-128.
[19] Turpie AG, Fisher WD, Bauer KA, et al.BAY 59-7939:an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement.A phase II dose-ranging study[J].J Thromb Haemost, 2005, 3(11):2479-2486.
[20] The ATLAS ACS TIMI 46 Trial.Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Subjects With Acute Coronary Syndromes[R].AHA 2008 Scientific Sessions ;November 10, 2008, New Orleans, LA.
[21] Venous Thromboembolic Event (VTE)Prophylaxis in Medically III Patients (MAGELLAN)[EB OL].http:clinicaltrials.gov ct2 show NCT00571649.
[22] The Einstein-Extension Study.Once-Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism[EB OL].http: clinicaltrials.gov ct2 show NCT00439725.
[23] The RECORD1 Study Group.Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty[J].N Engl J Med, 2008, 358(26):2765-2775.
[24] Kakkar AK, Brenner B, Dahl OE, et al.Extended thromboprophylaxis with rivaroxaban compared with short-term thromboprophylaxis with enoxaparin after total hip arthroplasty: the RECORD 2 Trial [abstract] [J].Blood,2007, 110.
[25] RECORD3 Investigators.Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty[J].N Engl J Med, 2008, 358(26):2776-2786.
[26] Turpie A, Bauer K, Davidson B, et al.Comparison of rivaroxaban-an oral, direct factor Xa inhibitor--and subcutaneous enoxaparin for thromboprophylaxis after total knee replacement (RECORD4:a phase 3 study)[R].European Federation of National Associations of Orthopaedics and Traumatology 2008 Annual Meeting ;May 29-June 1,2008;Nice, France.Abstract F85.